In recent years, immune checkpoint inhibitors that target PD-1/PD-L1 and/or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have emerged as effective immunotherapeutic agents in several types of cancer, profoundly changing the prognosis of a fraction of patients. This evidence concerns the gene CTLA4 and cancer.